AERRANE Inhalation/Liquid for

What is AERRANE

AERRANE is the brand name for **isoflurane**, a **volatile halogenated ether inhalation anesthetic** used in medical and veterinary settings to induce and maintain general anesthesia:contentReference[oaicite:1]{index=1}.

• Appearance: Clear, colorless liquid in amber bottles (100 mL):contentReference[oaicite:2]{index=2}.
• Primary indication: General anesthesia induction and maintenance during surgery:contentReference[oaicite:3]{index=3}.
• Features: Nonflammable, pungent odor, rapid induction and recovery:contentReference[oaicite:4]{index=4}.
• Use: Administered via calibrated vaporizer by trained anesthesia professionals:contentReference[oaicite:5]{index=5}.

How to use AERRANE

Safe administration requires expertise and precision:

• Administration route: Inhaled via vaporizer; used with oxygen or nitrous oxide:contentReference[oaicite:6]{index=6}.
• Dosing:
  • Induction: 1.5–3% vapor concentration, delivering anesthesia within 7–10 minutes:contentReference[oaicite:7]{index=7}.
  • Maintenance: 1–2.5% with N₂O; may require additional concentration if used with oxygen alone:contentReference[oaicite:8]{index=8}.
• Monitoring: Continuous pulse oximetry, ECG, blood pressure, end-tidal CO₂, and ventilation:contentReference[oaicite:9]{index=9}.
• Professional setting: Only used by qualified anesthesiologists or certified providers with airway management capabilities:contentReference[oaicite:10]{index=10}.

Mode of Action AERRANE

Isoflurane induces anesthesia through central nervous system depression:

• Neurotransmitter effects: Enhances GABA_A and glycine receptor activity, inhibits NMDA receptors, and alters ion channel functions:contentReference[oaicite:11]{index=11}.
• Spinal cord action: Promotes skeletal muscle relaxation by modulating inhibitory spinal receptors:contentReference[oaicite:12]{index=12}.
• Cardiovascular effects: Reduces systemic vascular resistance, may lower blood pressure, slightly increases heart rate, and dilates coronary vessels:contentReference[oaicite:13]{index=13}.
• Respiratory effects: Depresses tidal volume, increases PaCO₂, and requires ventilatory support:contentReference[oaicite:14]{index=14}.
• Cerebral impact: Elevates cerebral blood flow and intracranial pressure at higher concentrations:contentReference[oaicite:15]{index=15}.

AERRANE Interactions AERRANE

Isoflurane’s interactions are significant in anesthetic management:

• Opioids/N₂O: Reduce the MAC of isoflurane, so dosing must be adjusted:contentReference[oaicite:16]{index=16}.
• Neuromuscular blockers: Potentiates their effect—use reduced doses:contentReference[oaicite:17]{index=17}.
• CYP interactions: Isoflurane doesn’t significantly interact metabolically, but co-use with cardiac QT-prolonging drugs (e.g., amiodarone, dronedarone) is contraindicated due to arrhythmia risk:contentReference[oaicite:18]{index=18}.

Dosage of AERRANE

Dosage is individualized and monitored continuously:

• Induction: 1.5–3% isoflurane vapor by inhalation:contentReference[oaicite:19]{index=19}.
• Maintenance: 1–2.5% with N₂O; add 0.5–1% if using oxygen only:contentReference[oaicite:20]{index=20}.
• Pediatric use: Safety under age 2 not established; monitor neurocognitive effects in infants during prolonged exposure:contentReference[oaicite:21]{index=21}.
• Elderly adjustments: MAC decreases ~6% per decade over 40 years—lower concentrations needed:contentReference[oaicite:22]{index=22}.

Possible side effects of AERRANE

Like other anesthetics, isoflurane’s adverse effects are dose-dependent:

• Common (>5%): Agitation, cough, breath-holding, nausea, shivering, vomiting, laryngospasm, delirium:contentReference[oaicite:23]{index=23}.
• Cardiovascular: Hypotension, arrhythmias, possible coronary steal syndrome:contentReference[oaicite:24]{index=24}.
• Respiratory: Depressed ventilation, bronchodilation, airway irritation:contentReference[oaicite:25]{index=25}.
• Cerebral & hepatic: Increased intracranial pressure; rare reports of hepatitis and hepatic necrosis:contentReference[oaicite:26]{index=26}.
• Rare but serious: Malignant hyperthermia, perioperative hyperkalemia in certain neuromuscular disorders:contentReference[oaicite:27]{index=27}.

AERRANE Contraindications AERRANE

AERRANE must not be used in certain patient populations:

• Known hypersensitivity to isoflurane or other halogenated anesthetics:contentReference[oaicite:28]{index=28}.
• History or susceptibility to malignant hyperthermia:contentReference[oaicite:29]{index=29}.
• Prior unexplained hepatitis after inhalational anesthetic use:contentReference[oaicite:30]{index=30}.
• Contraindicated for obstetric anesthesia except for Cesarean section use:contentReference[oaicite:31]{index=31}.
• Caution with neuromuscular diseases (e.g., Duchenne’s dystrophy), liver dysfunction, intracranial hypertension, and high cardiac risk:contentReference[oaicite:32]{index=32}.

Storage of AERRANE

Maintain proper storage to ensure efficacy and safety:

• Room temperature (15–30 °C); protect from light:contentReference[oaicite:33]{index=33}.
• Keep in original amber bottle to prevent light exposure:contentReference[oaicite:34]{index=34}.
• Do not freeze; stable under various conditions:contentReference[oaicite:35]{index=35}.
• Ensure vaporizers are filled and maintained by trained personnel only:contentReference[oaicite:36]{index=36}.
• Handle spill and waste per institutional and environmental regulations.